Revenue, 2025

USD 2.71 Billion

Forecast, 2035

USD 42.61 Billion

CAGR, 2026-2035

30.40%

Report Coverage

United States

U.S. CAR T-Cell Therapies Market Trends for 2026

The U.S. CAR T-cell therapies market size was valued at US$ 2.71 billion in 2025 and is projected to grow to 3.43 billion in 2026. Forecasts suggest it will reach approximately US$ 42.61 billion by 2035, registering a CAGR of 30.40% during the period.

The U.S. CAR T-cell therapies market is growing because of the rising prevalence of blood cancers and continuing technological development in biomaterial production and cell engineering. The T-cell therapies come with precision medicine, a strong research and development pipeline with new targets, and increasing awareness in patients and healthcare professionals, which drives the growth of the market.

Key Takeaways

• U.S. CAR T-cell therapies industry poised to reach USD 3.43 billion by 2026.
• Forecasted to grow to USD 42.61 billion by 2035.
• Expected to maintain a CAGR of 30.40% from 2026 to 2035.
• The CAR T-cell therapy market was US$ 12.88 billion in 2025, rose to US$ 16.23 billion in 2026, and is projected to hit US$ 193.6 billion by 2035, growing at a 29.8% CAGR
• By drug type, the axicabtagene ciloleucel segment held the largest U.S. CAR T-cell therapies market revenue by 45% in 2025.
• By drug type, the tisagenlecleucel segment is expected to be the fastest-growing over the forecast period, 2026 to 2035.
• By indication, the lymphoma segment was dominant in the market by 35% in 2025.
• By indication, the acute lymphocytic leukemia segment is expected to register the fastest growth over the forecast period, 2026 to 2035.
• By end user, the hospitals segment was dominant in the market by 60% in 2025.
• By end user, the cancer treatment centers segment is expected to register the fastest growth over the forecast period, 2026 to 2035.

What is Supporting the Rapid Growth of the Market in the U.S.?

The U.S. CAR T-cell therapies market is rapidly growing as major biopharmaceutical companies, focused on emerging and commercializing immunotherapies to continue to increase cancer treatment. CAR T-cell therapy refers to a type of immunotherapy used for various types of blood cancer, such as lymphoma, leukemia, and multiple myeloma. It functions by turning T-lymphocytes (T-cells) into more effective cancer-killing machines. In CAR T-cell therapy, medical care professionals introduce a novel gene into T cells that variations cells so them to recognize and kill cancerous cells. Chimeric antigen receptor (CAR)-T-cell therapies have presented amazing efficacy in the treatment of hematologic cancer.

Significant Investments in 2025

U.S. CAR T-Cell Therapies Market Trends

• In January 2025, blood cancer treatment in India, Immuneel Therapeutics, launched Qartemi, a revolutionary CAR T-cell therapy specifically designed for adult patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma. This innovative blood cancer therapy harnesses the power of the patient's own immune system to fight cancer, offering new hope to those who have exhausted conventional treatment options.
• In August 2025, SMS Hospital will be the first govt hospital to have established a separate department for clinical haematology (DCH). SMS Hospital has established a Department of Clinical Haematology (DCH) for the treatment of all types of haematological cancers and blood disorders, including bleeding disorders and bone marrow transplants.

What is the Role of AI in the Growth of the U.S. CAR T-Cell Therapies Market?

Integration of AI in North American veterinarian care drives the growth of the market, as increasing application of AI-driven technologies leads to improved production efficiency and precision, optimizes logistics, and lowers the expenses of CAR T-cell therapy. AI-driven technology assists in recognizing suitable patients for therapy and supports monitoring therapy progression and predicting responses to treatment.

AI-based technology in CAR-T cell therapy has huge potential to offer important advances in the manufacturing of CAR-T cells and management of lymphoma and leukemia.  This technology has powered sensors that continuously monitor complex parameters such as cell count, growth, and nutrient levels in bioreactors. This offers real-time information for enhancing culture conditions and ensuring a consistent and high-quality product.

Executive Summary Table

Segmental Insights

By Drug Type

Explanation

• Axicabtagene Ciloleucel provides CAR-T therapy and holds 45% and dominates due to strong clinical adoption and proven efficacy.
• Tisagenlecleucel delivers targeted CAR-T treatment and captures 25% but does not dominate as adoption is limited to specific indications.
• Brexucabtagene Autoleucel offers CAR-T therapy for select cancers and holds 15% but does not dominate due to narrower patient base and specialized use.
• Others include emerging CAR-T candidates and represent 15% but do not dominate due to early-stage development and limited market presence.

Why the Axicabtagene Ciloleucel Segment Dominated the Market?

By drug type, the Axicabtagene Ciloleucel segment led the U.S. CAR T-cell therapies market by 45% , as Axicabtagene ciloleucel is applied to treat follicular lymphoma and large B-cell lymphoma that has come back or after 2 or more lines of management did not work well.

On the other hand, the tisagenlecleucel segment is projected to experience the fastest CAGR from 2025 to 2034, as it is used to treat B-cell acute lymphoblastic leukemia (ALL) that has come back a second time or later time or after other drugs did not work better in patients up to 25 years of age.

By Indication

Explanation

• Lymphoma receives targeted therapies and holds 35% and dominates due to high prevalence and strong treatment focus.
• Acute Lymphocytic Leukemia (ALL) requires specialized interventions and captures 20% but does not dominate due to smaller patient population.
• Chronic Lymphocytic Leukemia (CLL) is treated with precision therapies and holds 10% but does not dominate as incidence is lower.
• Multiple Myeloma (MM) benefits from advanced treatments and represents 15% but does not dominate due to niche patient base.
• Others include rare hematologic cancers and capture 20% but do not dominate due to fragmented and limited prevalence.

Why the Lymphoma Segment Dominated the Market?

By indication, the lymphoma segment is dominant in the U.S. CAR T-Cell therapies market by 35% in 2025, as in chimeric antigen receptor-modified (CAR) T-cell therapy, personalized CD19 has transformed the treatment of relapsed or refractory B-cell lymphomas.  The genetically improved T-cells persist in the body for months or even years, persistently monitoring for and offensive cancer cells to avoid relapse.

The acute lymphocytic leukemia segment is expected to experience the fastest growth from 2025 to 2034, driven by the development of CAR T-cells, which are universally applicable allogeneic products. These CAR T-cells are derived from healthy donors, ensuring a plentiful supply of healthy T-cells that are unaffected by chemotherapy or cancer itself. For patients with highly aggressive ALL that has relapsed after multiple treatments, CAR T-cell therapy provides renewed hope and a potential pathway to a cure.

By End-user

Explanation

• Hospitals provide comprehensive cancer care and hold 60% and dominate due to high patient volumes and integrated treatment facilities.
• Cancer Treatment Centers specialize in oncology services and capture 40% and are gaining momentum due to focused expertise and advanced therapies.

Why is the Hospitals Segment Dominant in the Market?

By end-user, the hospitals segment led the U.S. CAR T-cell therapies market by 60% in 2025, as CAR T-cell therapy requires a short treatment time required administered with a single infusion at most, two weeks of inpatient care, and then it’s done. In the hospital, healthcare professionals use CAR T-cell therapy to manage cancer by genetically engineering a patient's own T cells to attack cancer cells. CAR T-cell therapy is often considered for patients who have not responded well to ideal treatments such as chemotherapy or have experienced relapse. The application of CAR T-cell therapy is not limited to specific types of cancer.

The cancer treatment centers segment is projected to experience the fastest CAGR from 2025 to 2034, as this center serves as a central hub for those patients' needs, offering a full spectrum of cancer services, involving screening and prevention, research, treatment, diagnosis, rehabilitation, emotional balance, and survivorship programs. It also offers various psychosocial support services to help patients and their loved ones manage the disease and its treatment.

Global CAR T-Cell Therapy Market Growth

The CAR T-cell therapy market size stood at US$ 12.88 billion in 2025, grew to US$ 16.23 billion in 2026, and is forecast to reach US$ 193.6 billion by 2035, expanding at a CAGR of 29.80% from 2026 to 2035.

U.S. CAR T-Cell Therapies Market – Value Chain Analysis

R&D

The research and development (R&D) technology for U.S. CAR T-cell therapies mainly includes a multi-stage process that includes genetic engineering, cell manufacturing, and extensive quality control. 

Key Players:  hermo Fisher Scientific and Corning Life Sciences

Clinical Trials

Clinical trials of U.S. CAR T-cell therapies involve patient evaluation, collection of the patient's T-cells, and their genetic engineering into CAR T-cells in a lab.

Key Players: Merck KGaA and Evonik

Patient Services

CAR T-cell therapy provides patient services such as personalized, targeted treatment, inclusive supportive care, and a huge strength for long-term remission.

Key Players: Collplant Biotechnologies and Chondrex, Inc.

SWOT Analysis

Strengths

• The strong presence of major companies like Gilead, Novartis, and Bristol-Myers Squibb, along with specialized hospital centers, makes up an impressive market share in administration.
• Several commercial products, such as Yescarta and Kymriah, have already gained a strong foothold with a solid patient base.

Weaknesses

• The high costs of medications and hospital services, along with significant logistical challenges like long turnaround times, create major issues.
• There is also a risk of serious side effects, including cytokine release syndrome (CRS) and neurotoxicity.

Opportunities

• Current research into CAR-T therapies for solid tumors shows considerable growth potential that goes beyond the current focus on blood-related conditions.
• Innovations in gene editing and next-generation CAR-T designs are aimed at improving both effectiveness and safety.

Threats

• Issues related to insurance and reimbursement for expensive therapies may limit patient access and slow market growth.
• Fierce competition for innovation in a maturing market puts pressure on developers to prove their superiority.

Top Companies in the U.S. CAR T-Cell Therapies Market

• Johnson & Johnson Services, Inc.
• ALLOGENE THERAPEUTICS
• Lonza
• Aurora Biopharma
• Cartesian Therapeutics, Inc.
• Novartis
• Bristol-Myers Squibb company
• Gilead Sciences
• Curocell Inc
• JW Therapeutics

Top Key Players' Offerings in the U.S. CAR T-Cell Therapies Market

Recent Developments in the U.S. CAR T-Cell Therapies Market

• In June 2025, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) had approved label updates for both of its CAR T cell therapies, Breyanzi for the treatment of large B cell lymphoma (LBCL) and other lymphomas, and Abecma for the treatment of multiple myeloma.
• In March 2025, AstraZeneca entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that have demonstrated promising early clinical activity. The EsoBiotec Engineered NanoBody Lentiviral (ENaBL) platform empowers the immune system to attack cancers and could offer many more patients access to transformative cell therapy treatments delivered in just minutes, rather than the current process, which takes weeks.
• In September 2025, ImmunityBio, Inc., a leading immunotherapy company, announced novel paradigm-changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA reverses lymphopenia in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer (NSCLC), with this reversal resulting in significant prolonged median overall survival (mOS).

Segments Covered in the Report

By Drug Type

• Axicabtagene Ciloleucel
• Tisagenlecleucel
• Brexucabtagene Autoleucel
• Others

By Indication

• Lymphoma
• Acute Lymphocytic Leukemia
• Chronic Lymphocytic Leukemia (CLL)
• Multiple Myeloma (MM)
• Others

By End User

• Hospitals
• Cancer Treatment Centers